13-valent PCV (PCV13), was included in the second year of life for Aboriginal children. From January 2005, PCV7 in a 3 + 0 schedule was universally funded for all Australian children aged <2 years and from July 2011, PCV7 was replaced by PCV13.
We previously reported on declining all-cause pneumonia hospitalization rates between 1996 and 2005 in Aboriginal and non-Aboriginal children in Western Australia (WA) and the pathogens associated with these hospitalizations [5, 13] . Here, we extend this work by examining rates of all-cause pneumonia hospitalizations after implementation of the universal PCV program and identifying the pathogens associated with pneumonia hospitalizations in children prior to and following introduction of the universal PCV program.
METHODS

Setting and Cohort
Western Australia covers a total land area of 2.5 million km 2 with a population of nearly 2.6 million [14] , 3 .6% of whom identify as Aboriginal [15] . A cohort of live births between 1996 and 2012 was identified through the Midwives' Notification System and Birth Register. Data pertaining to children in the birth cohort were then extracted from the Hospital Morbidity Data Collection, PathWest Laboratory Medicine Database (PathWest) and the WA Notifiable Infectious Diseases Database (WANIDD) and probabilistically linked by the WA Data Linkage Branch (WA DLB) [16] . Aboriginal status of the child was derived by the WA DLB [17] .
Pathology Data
PathWest is the sole public pathology provider in WA and also processes referred samples from private pathology laboratories in WA. Further details on PathWest are provided elsewhere [13] . We extracted pathology data on respiratory specimens collected from children in the birth cohort between January 2000 and December 2012. At PathWest, respiratory samples received for viral testing during the study period were routinely investigated for RSV, influenza viruses A/B, human adenoviruses, and parainfluenza viruses (PIVs). Testing for human metapneumovirus (hMPV) was available from 2003 and routinely tested from 2008. Testing for other respiratory viruses, such as human picornaviruses, was performed only on request. Culture for bacterial pathogens was routinely performed following submission of blood cultures and/or other sterile fluids. Culture of lower respiratory specimens including sputa, endotracheal aspirates, and bronchoalveolar lavage specimens was performed for respiratory pathogens including S. pneumoniae and Haemophilus influenzae, and positive culture results were reported only if a predominant or pure growth of a pathogen was identified from high-quality or invasive specimen. Testing for fastidious pathogens (eg, Bordetella pertussis, Mycoplasma pneumoniae) was performed by culture, polymerase chain reaction (PCR), or serology upon request.
Pathology data from nasal/nasopharyngeal (NP), throat, tracheal, bronchial, sputum, lung, pleural fluid, blood, cerebrospinal fluid (CSF), or serum specimens were extracted from PathWest laboratory information systems. Nasal/NP specimens (for viruses) included combined nose and throat, NP, and perand postnasal swabs and aspirates. For respiratory bacterial pathogens, any positive bacterial culture or positive PCR result from normally sterile sites (blood, pleural fluid, lung biopsy, and CSF) or significant growth from lower respiratory tract samples (as described above) was considered to be the causative pathogen for that episode of infection. For atypical bacterial pathogens, positive PCR or culture identifications from nasal/NP and throat swabs were also considered valid. For viral pathogens, positive results from any specimens (excluding CSF) on which respiratory virus testing was conducted (including using antigen detection [eg, immunofluorescent antibodies], PCR, viral culture, and serology) were considered to be the etiological cause. If multiple pathogens (bacterial, viral, or in combination) were identified in the same specimen (co-detection), the episode of infection was considered to be caused by >1 pathogen (i.e., coinfection).
Notifiable Infectious Disease Data
WANIDD is an intranet-based real-time database storing information on notifiable infectious diseases in WA. It relies on mandatory reporting by doctors and laboratories, and is curated by the WA Department of Health. We extracted WANIDD records pertaining to children in the birth cohort, with notifications for influenza, pertussis, and IPD.
Hospital Morbidity Data
We identified hospital records (hereafter referred to as hospital admissions) with an admission and separation date between January 1996 and December 2012 and having a pneumonia-related diagnosis code (International Table 1 ) listed in the principal diagnosis field or in any of the 20 additional diagnosis fields. Interhospital transfers and transfers within the same hospital, with the same principal diagnosis, were merged into a single admission. Pneumonia-related admissions within 14 days of a previous pneumonia-related separation were merged and classified as a single episode. ICD codes for admissions relating to skin infections (Supplementary Table 1) were assessed as a negative control to investigate trends in hospitalizations unrelated to vaccination.
Linking of Records Relating to Same Episode of Hospitalization
WANIDD records were first combined with a PathWest record and if the date of onset on WANIDD matched the reporting date (±48 hours) on PathWest for the same disease/pathogen, it was considered to be the same episode of infection. As pathology data were available only from 2000, we restricted the hospitalization data to those pneumonia-related hospital admissions with an admission and separation date between January 2000 and December 2012. The combined pathology and WANIDD records were linked to a pneumonia-related hospital admission record if a specimen was collected 48 hours before or after the date of admission (Figure 1) . If the same person had multiple pathology and/or WANIDD records within the 48-hour period, results were merged onto the same admission record.
Statistical Analyses
Using person-time at risk from pneumonia-related hospital episodes as the denominator, annual age-specific incidence rates of all-cause pneumonia hospitalizations were calculated for Aboriginal and non-Aboriginal children. We estimated incidence rate ratios with 95% confidence intervals (CIs), across different age groups, between the pre-PCV period (1996) (1997) (1998) (1999) (2000) and universal PCV period (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . Yearly incidence trends were analyzed by log-linear modeling using negative binomial regression (nbreg) in Stata software and presented graphically as log-transformed rates. Interrupted time trend models were used to examine differences in trend between the pre-PCV and universal PCV periods. To test the impact of the universal vaccine program on population-based trends of pneumonia and to investigate the annual changes in incidence from 1996 to 2012, interrupted linear time trend modeling was conducted with a break point in the year 2001 for Aboriginal children and 2005 for non-Aboriginal children. For comparisons with the negative control, we compared linear trends in the pre-PCV and universal PCV periods only. Fitted trends from these models are presented graphically.
To investigate the etiology of pneumonia, pneumonia-related hospital admissions were used. Pathogen-specific pneumonia hospitalization rates in children aged <5 years were calculated for Aboriginal and non-Aboriginal children, comparing the pre-universal PCV period (2000) (2001) (2002) (2003) (2004) to the universal PCV period (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . Data cleaning and analysis were performed using SPSS (version 23), EpiBasic (version 3), and Stata (version 13.1) software.
Ethical Approvals
This study was approved by the WA Department of Health Human Research Ethics Committee, the WA Aboriginal Health Ethics Committee, and the University of WA Human Research Ethics Committee.
RESULTS
The birth cohort comprised 469 589 children born in WA between 1996 and 2012, 6.7% of whom identified as being Aboriginal. A total of 2428 children (0.5%) had died by 2012. The total person-years at risk available for the study was 3 753 975. There were 541 207 hospital admissions relating to the children in the birth cohort, 2.9% (n = 15 809) of which were identified as pneumonia related. These admissions were further collapsed into 15 175 pneumonia-related episodes. Aboriginal children accounted for 32.4% (n = 4914) of these episodes. 
Pneumonia-Related Hospital Episodes
Overall, pneumonia hospitalization rates in children aged ≤16 years were 6.7 (95% CI, 6.4-6.9) times higher in Aboriginal than in non-Aboriginal children (19.4 vs 2.9 per 1000 childyears, respectively). Pneumonia hospitalization rates were highest in Aboriginal children aged 6-11 months (64.0/1000 child-years) and in non-Aboriginal children aged 12-23 months (7.3/1000 child-years).
For all children, pneumonia hospitalization rates declined over the study period (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . Comparing the pre-PCV with universal PCV periods, the age groups with the greatest declines were children aged 6-11 months (50%-63% decline Aboriginal; 39%-46% decline non-Aboriginal) and 2-4 years (54%-66% decline Aboriginal; 32%-44% decline non-Aboriginal; Table 1 ). The disparity between Aboriginal and non-Aboriginal children for all-cause pneumonia-related hospital episodes declined significantly from the pre-PCV period to the universal PCV period by 35% in children aged 2-4 years, by 30% in those aged 6-11 months, and by 27% in those aged 12-23 months (Table 1) .
Log-linear modeling showed significant declines (P < .001) in the annual incidence of all-cause pneumonia hospitalizations in both Aboriginal and non-Aboriginal children in all age groups over the study period, with the largest decline (by 8.1% per year) seen in Aboriginal children aged 2-4 years. A significant (P = .007) stepdown trend was observed in the annual reduction rates in Aboriginal children aged 12-23 months (Figure 2 ). In non-Aboriginal children, a decline was observed in annual trends from 2002 to 2008 in all age groups; hospitalization rates remained steady thereafter. There was no significant step-down trend in the universal PCV period for non-Aboriginal children. In contrast, there were increases in skin infection hospitalizations in the universal PCV period in most age groups in both Aboriginal and non-Aboriginal children (Figure 3 ).
Etiology of Pneumonia Hospitalizations in Children Aged ≤16 Years
Nearly half (49.4% [n = 6693]) of all pneumonia hospitalizations linked to a PathWest and/or WANIDD record for respiratory pathogen testing and, of those, 41.6% (n = 2785) had ≥1 respiratory pathogen identified (Figure 1 ). More than 1 pathogen was co-detected in 339 (12.2%) of admissions.
The frequency and admission rates of pathogens identified in children hospitalized with pneumonia who had a linked pathology record with 1 or more pathogens identified (hereafter known as pathology-confirmed pneumonia hospitalizations) are presented in Table 2 . In both Aboriginal and non-Aboriginal children, RSV was the most commonly identified viral respiratory pathogen with RSV-confirmed pneumonia hospitalization rate of 89.6/100 000 child-years in Aboriginal children and 26.6/100 000 child-years in non-Aboriginal children (Table 2) . Influenza A, human adenovirus, and picornavirus were the next most common viral pathogens identified in Aboriginal children with pathology-confirmed pneumonia hospitalizations. Streptococcus pneumoniae (9.7%; 32.9/100 000 child-years) was the most common bacterial pathogen identified in Aboriginal children, followed by Haemophilus influenzae (3.9%; 13.3/100 000 childyears). In non-Aboriginal children, the most commonly identified bacterial pathogen was M. pneumoniae (11.7%; 8.4/100 000 child-years) followed by S. pneumoniae, and among non-RSV viral pathogens, PIV and hMPV were most common ( Table 2) . Compared to the pre-universal PCV period, there was an overall decline in the rate of RSV-specific pneumonia hospitalizations (from 145.1 to 73.1 per 100 000 child-years in Aboriginal children and from 42.6 to 21.9 per 100 000 childyears in non-Aboriginal children; P < .05) in children aged <16 years in the universal PCV period, but the level of decline varied in the different age groups (Tables 2-4 ). Other changes observed over the study period included a significant reduction (P = .008) in influenza A-specific pneumonia rates in non-Aboriginal children aged 12-23 months and 2-4 years, although declines in Aboriginal children did not reach statistical significance (Table 3 and 4) . Compared to pre-universal PCV period, S. pneumoniae-specific pneumonia rates showed a 60% reduction in non-Aboriginal children aged 12-23 months in the universal PCV period, whereas the rates were 4.3 times higher (P = .52) in Aboriginal children aged 12-23 months. We previously showed declining trends in pneumonia hospitalizations from 1996 to 2005 [5] . Using extended population-based data, we have shown sustained declines in all-cause pneumonia hospitalization rates in WA in both Aboriginal and non-Aboriginal children in all age groups after the implementation of the universal PCV program. In contrast, skin infectionrelated hospitalizations showed similar declines in the pre-PCV period but rates increased across almost all age groups in the universal PCV period, suggesting a positive impact of PCV on pneumonia-related hospitalizations.
We observed a 40% reduction in pneumonia-related hospitalizations in WA children aged <2 years in the universal PCV period. Several clinical trials have demonstrated the efficacy of PCV in preventing IPD and all-cause pneumonia in young children [18] . Our estimates are within the range reported by these clinical trials and are similar to the findings of a national study conducted in the United States showing a decline of 39% in allcause pneumonia hospitalization rates in children aged <2 years [19] . An estimated 32% decline in pneumonia hospitalizations in this age group was observed in a national study in Australia [20] . Elsewhere, studies have reported modest declines in pneumonia hospitalizations in the post-PCV period, ranging from 15% to 30% [21] [22] [23] [24] .
To our knowledge, the etiology of childhood pneumonia hospitalizations in the pre-and post-PCV periods has never been reported in Australia. At least 1 viral pathogen was identified in 73% of children with pathology-confirmed pneumonia hospitalizations (Figure 1 ). Over the study period, RSV was the most commonly identified pathogen in both Aboriginal and non-Aboriginal children hospitalized with pneumonia, accounting for nearly 34% of all pathogens identified. Studies have shown that RSV is the most frequently identified pathogen in children diagnosed with pneumonia, especially in younger children [1, 25, 26] . Streptococcus pneumoniae was the most common bacterial pathogen identified in Aboriginal children, with hospitalization rates 8 times higher than in non-Aboriginal children. Mycoplasma pneumoniae was the most commonly identified pathogen in non-Aboriginal children. This was not due to differential testing based on indigeneity: the rate of M. pneumoniae-specific hospitalization was similar for Aboriginal and non-Aboriginal children (Table 2 ) and the rate of M. pneumoniae tests was lower in non-Aboriginal children (4.3/10 000 child-years) compared with that of Aboriginal children (10.0/10 000 child-years). Mycoplasma pneumoniae-specific hospitalization rates appeared to rise with increasing age in both Aboriginal and non-Aboriginal children, as documented elsewhere [26, 27] .
Our data show marked declines in RSV-, influenza A-, and PIV-specific pneumonia hospitalization rates from the pre-universal to universal PCV periods, especially in young non-Aboriginal children. Studies have documented the role of infecting viruses in facilitating bacterial spread in the pathogenesis pathway of pneumonia, whereby a favorable environment for bacterial growth is created by the cytopathic effect of the virus on the mucociliary barrier in the bronchial epithelium [25, 28] . Furthermore, the broader impact of PCV in preventing hospitalization for viral pneumonia, most likely by prevention of superimposed bacterial coinfections, has been shown in a randomized trial [29] . Despite overall declines in pneumonia hospitalizations in Aboriginal children, the relative contribution of S. pneumoniae hospitalizations increased over the study period. This is likely a reflection of small numbers and potentially increased testing in Aboriginal children [30] . Also, the earlier implementation of the PCV program in Aboriginal children in mid-2001 may possibly have had an impact on pathogen rates in the pre-universal PCV period itself.
We have relied on ICD codes to identify pneumonia-related hospitalizations. Though the use of ICD codes in identifying pneumonia diagnosis has been validated, an element of error due to misclassification or changes in coding practices remains [31] . As with most ecological studies, the main limitation is the lack of individual immunization data to accurately assess the impact of PCV on the incidence of all-cause pneumonia, and our results might be confounded by other factors such as changes in clinical and diagnostic practices. We are currently assessing the impact of PCV programs in children through a cross-jurisdictional record linkage study with individual immunization data from WA and New South Wales [32] .
A strength of our study is the inclusion of pathology data to assess pathology-confirmed pneumonia, but only half of all hospital admissions for pneumonia linked to any pathology record. This is likely because the diagnosis of pneumonia is based on clinical and/or radiological evidence and, hence, a significant proportion of children hospitalized for pneumonia will not undergo testing. This, in addition to the limited sensitivity of current diagnostics, particularly for bacterial pneumonia, will lead to underestimation of the pathogen-specific pneumonia hospitalization rates. Also, there have been changes in respiratory pathogen testing patterns in WA over the study period [30] . For example, hMPV testing at PathWest was conducted only upon request from 2003-2007 and switched to routine testing from 2008. These changes coupled with temporal changes in the sensitivity and specificity of current tests could also affect pathogen estimates. As increased use of more sensitive molecular diagnostic methods occurred later in the study, it is possible that the decreasing incidence of viral pneumonia is underestimated due to artificially low rates in earlier years.
CONCLUSIONS
The burden of pneumonia hospitalizations remains high in children aged <5 years. PCV has had a significant impact in reducing pneumonia-related hospitalizations in WA, especially in the Aboriginal population. Though the disparity in pneumonia hospitalization rates between the Aboriginal and non-Aboriginal population has decreased after the implementation of the universal PCV program, young Aboriginal children are still hospitalized with pneumonia at 7 times the rate of their non-Aboriginal counterparts. A multitude of pathogens were identified with respiratory viruses being most common. In addition to all-cause pneumonia, the incidence of viral pneumonia has also declined with PCV vaccination. The high burden of RSV-and PIV-related pneumonia hospitalizations highlights the need for acceleration of development and/or roll-out of vaccines targeting these pathogens.
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